Compare · ABT vs PBH
ABT vs PBH
Side-by-side comparison of Abbott Laboratories (ABT) and Prestige Consumer Healthcare Inc. (PBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PBH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.63B, about 71.0x PBH ($2.24B).
- Over the past year, ABT is down 32.2% and PBH is down 44.5% - ABT leads by 12.3 points.
- ABT has been more active in the news (6 items in the past 4 weeks vs 1 for PBH).
- ABT has more recent analyst coverage (25 ratings vs 12 for PBH).
- Company
- Abbott Laboratories
- Prestige Consumer Healthcare Inc.
- Price
- $90.44-0.69%
- $47.67+1.07%
- Market cap
- $158.63B
- $2.24B
- 1M return
- +4.00%
- -12.60%
- 1Y return
- -32.20%
- -44.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2005
- News (4w)
- 6
- 1
- Recent ratings
- 25
- 12
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye allergies/redness relief, Compound W wart removals, Debrox ear wax removals, DenTek for PEG oral care, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest PBH
- Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference
- SEC Form 10-K filed by Prestige Consumer Healthcare Inc.
- Amendment: CFO & COO Sacco Christine covered exercise/tax liability with 1,091 shares, decreasing direct ownership by 2% to 57,374 units (SEC Form 4)
- Prestige Consumer downgraded by Oppenheimer
- Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health
- Senior VP Operations Zerillo Jeffrey sold $18,350 worth of shares (351 units at $52.28), decreasing direct ownership by 0.83% to 41,810 units (SEC Form 4)
- Senior VP Operations Zerillo Jeffrey sold $16,580 worth of shares (305 units at $54.36) and covered exercise/tax liability with 351 shares, decreasing direct ownership by 2% to 42,161 units (SEC Form 4)
- CFO & COO Sacco Christine covered exercise/tax liability with 991 shares, decreasing direct ownership by 1% to 71,636 units (SEC Form 4)
- Chief Executive Officer Lombardi Ronald M. covered exercise/tax liability with 2,543 shares, decreasing direct ownership by 0.68% to 373,465 units (SEC Form 4)